Although, more expensive, the latter three offers some advantages in terms of less risk of hypoglycaemia and weight gain (analogue insulins), weight loss and cardiovascular benefits (SGLT-2 inhibitors and GLP-1 analogues) [19, 20]. Here, INS is linked to Hypoglycemia.